TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* 18 to 80 years of age, inclusive~* Confirmed diagnosis of ALS or probable ALS~* Clinical history of pseudobulbar affect~* If female, must not be pregnant, breast-feeding, or planning a pregnancy during the course of the study, and must have a negative urine pregnancy test prior to start of study~* If female, must have been practicing an established method of birth control for at least the prior month (oral contraceptive tablets, hormonal implant device, intrauterine device, diaphragm and contraceptive cream or foam, condom with spermicide, tubal ligation, or abstinence) or be surgically sterile or post-menopausal~* Must be willing to not take any prohibited medications during participation in the study~Exclusion:~* Known sensitivity to quinidine or opiate drugs (codeine, etc.)~* On any anti-depressive medication~* Recently (within two months) diagnosed with ALS~* Currently participating in, or who within the past 30 days have participated in, the study of another investigational new drug~* Previously received treatment with co-administration of dextromethorphan and quinidine~* History of substance abuse within the past two years~* Women who are pregnant or likely to become pregnant during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males, 45 years or older, with benign prostatic hyperplasia, including lower urinary tract symptoms for at least 6 months prior to Visit 1 and an International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 2.~* Agree not to use approved or experimental benign prostatic hyperplasia or erectile dysfunction treatments anytime during the study~* Have not taken finasteride or dutasteride therapy, any other lower urinary tract symptom (LUTS) therapy or phosphodiesterase type 5 (PDE5) inhibitors for specified duration of time prior to Visit 2.~* Have a prostate specific antigen (PSA) score within acceptable range defined for study or negative biopsy of the prostate for cancer within 12 months of Visit 1.~Exclusion Criteria:~* History of urinary retention or lower urinary tract (bladder) stones 6 months before the start of the study~* History of bladder outlet obstruction or urethral obstruction due to stricture, valves, sclerosis, or tumor.~* History of cardiac conditions including angina requiring certain treatment with nitrates, heart disease or coronary conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for a specified time before starting the study.~* Certain neurological conditions associated with bladder problems or injuries to the brain or spinal cord within a specified time before starting the study.~* Nitrate use

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): placebo tablet
- 2 (Type: ACTIVE_COMPARATOR): 2.5 mg tadalafil tablet
- 3 (Type: ACTIVE_COMPARATOR): 5 mg tadalafil tablet
- 4 (Type: ACTIVE_COMPARATOR): 10 mg tadalafil tablet
- 5 (Type: ACTIVE_COMPARATOR): 20 mg tadalafil tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of complicated lower urinary tract infection or pyelonephritis~Exclusion Criteria:~* Women who are pregnant, nursing or of child-bearing potential and not using a medically accepted, effective method of birth control~* History of moderate or severe hypersensitivity reactions to antibiotic medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crizanlizumab for Treating COVID-19 Vasculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing to provide written informed consent~2. Willing to comply with all study procedures and be available for the duration of the study~3. Male or female ≥ 18 years of age~4. SARS-CoV-2 infection (COVID-19) within the past 10 d documented by laboratory test (nucleic acid test (NAT) or reverse transcriptase-polymerase chain reaction (RT-PCR))~5. Currently hospitalized~6. Symptoms of acute respiratory infection (at least one of the following: cough, fever \> 37.5°C, dyspnea, sore throat, anosmia),~7. Radiographic evidence of pulmonary infiltrates~8. Requiring supplemental oxygen or the peripheral capillary oxygenation saturation (SpO2) \< 94% on room air at screening~9. Elevated D-Dimer \> 0.49 mg/L~10. Negative pregnancy test for females of childbearing potential~Exclusion Criteria:~1. Use of home oxygen at baseline~2. Current use of mechanical ventilation~3. Inability to provide consent~4. Do not intubate status~5. Prisoner or incarcerated~6. Pregnancy or Breast Feeding~7. Participation in other interventional therapy trials for COVID-19.~8. International normalized ratio (INR) \> 3 or activated partial thromboplastin time (aPTT) \> 60

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crizanlizumab (Type: EXPERIMENTAL): Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
- Placebo Saline (Type: ACTIVE_COMPARATOR): 0.9% saline 100 ml IV once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of SpHb Monitoring on Transfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 1,2 patients from 15 to 60 years old scheduled for neurosurgical procedure~Exclusion Criteria:~* Exclusion criteria included significant liver or renal disease, coagulopathy, pregnancy, anemia, and patients scheduled for procedures with excepted low blood loss.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: NO_INTERVENTION): Control Group received standard anesthesia care including intraoperative blood sampling when estimated blood loss was ≥15% of total blood volume and transfusion when hemoglobin was ≤10 g/dL.
- SpHb Group. (Type: EXPERIMENTAL): Continuous non-invasive hemoglobin monitoring (SpHb monitoring) was provided to the anesthesiologist to influence administration of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing selective frontotemporal tumor resection.~* Age ≥18 years.~* Obtain written informed consent.~Exclusion Criteria:~* Refusal to provide written informed consent.~* Preoperative severe cognitive impairment (mini-mental state examination, MMSE ≤ 20).~* Allergic to the study drug.~* History of psychotropic drugs within past 30 days.~* Pregnant or lactating women.~* History of traumatic brain injury or neurosurgery.~* Severe bradycardia (heart rate less than 40 beats per minute), sick sinus syndrome or second-to-third degree atrioventricular block.~* Severe hepatic or renal dysfunction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DEX group (Type: ACTIVE_COMPARATOR): The DEX group will receives dexmedetomidine intraoperative.
- Placebo group (Type: PLACEBO_COMPARATOR): The placebo group will receives 0.9% saline intraoperative.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with type 2 diabetes mellitus; 2. HbA1c ≥8% but ≤12%; 3.Fasting C-peptide ≥1.0 ng/ml; 4. Subject will be drug naïve; 5. Body mass index ≤40 kg/m2.~Exclusion Criteria:~1. Symptoms of poorly controlled diabetes; 2. Chronic or repeated intermittent corticosteroid treatment ; 3. Calculated creatinine clearance \<60 ml/min or serum creatinine \>132.6 μmol/L (\>1.5 mg/dL) for men, \>123.8 μmol/L (\>1.4 mg/dL) for women; 4. Creatine Kinase ≥3x ULN; 5.Abnormal TSH value at screening will be further evaluated by free T4, subjects with an abnormal free T4 will be excluded; 6. History of administration of any antihyperglycaemic therapy for a total of 28 days or for more than three consecutive days or a total of seven non-consecutive days during the eight weeks prior to screening; 7. Current treatment with a strong CYP3A4/5 inhibitor; 8. Prior treatment with saxagliptin or any DPP-4 inhibitor; 9. Significant or history of cardiovascular disease, renal disease, psychiatric disorders, Immunocompromised individuals, hemoglobinopathies, liver disease, Pancreatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5 mg + Metformin (500 mg with titration) (Type: EXPERIMENTAL): Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
- Saxagliptin 5 mg + Placebo (Type: ACTIVE_COMPARATOR): Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
- Metformin (500 mg with titration) + Placebo (Type: ACTIVE_COMPARATOR): Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EFFICACY: Hopewell Hospitalist: A Video Game Intervention to Increase Advance Care Planning by Hospitalists

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Hospital Inclusion Criteria:~* Value-based delivery model of care (Bundled Payment Care Initiative)~* Staffed by Sound Physicians for at least 2 quarters~* Advance care planning billing rate in prior quarter greater than 0 percent~* Employs a nurse liaison~* Hospitalist chief approval to approach hospitalists~Hospital Exclusion Criteria:~* Sound Physicians no longer staffing the hospital~* Not staffed by Sound Physicians for at least 2 quarters~* Advance care planning billing rate in prior quarter of 0 percent~* Does not employ a nurse liaison~* Hospitalist chief disapproval to approach hospitalists~* Hospitalist chief does not provide contact information for hospitalists~* Target number of hospitalists for the step has been met or exceeded~Hospitalist Inclusion Criteria:~* Employed by Sound for at least 2 quarters and staffing an eligible hospital for at least 1 quarter~* ACP billing rate in prior quarter greater than 0 percent or answers eligibility question affirming use of ACP billing codes~* Provides informed consent~* Name matches a name in the contact list for the sample; OR is verified by communication through an employer-based email address~* Receipt of a functional iPad within study step time frame~Hospitalist Exclusion Criteria:~* Not employed by Sound for at least 2 quarters and staffing an eligible hospital for at least 1 quarter~* ACP billing rate in prior quarter of 0 percent or answers eligibility question refusing use of ACP billing~* Does not provide informed consent~* Provides consent after the given deadline for consenting~* Name does not match a name in the contact list for the sample; OR cannot be verified by communication through an employer-based email address~* Receipt of a nonfunctional iPad within study step time frame~* If the number of participants who consent per site exceeds targets, then participants who are part-time employees will be preferentially excluded

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Usual Care Control (Type: NO_INTERVENTION): The control arm occurred prior to receipt of the video game intervention. Each hospital group 'crossed over' from control to intervention at a randomized time point based on their assignment to the 'step' of the trial.
- Video Game Intervention (Type: EXPERIMENTAL): Each hospital group 'crossed over' from control to intervention at a randomized time point. Physicians working at these hospitals, who agreed to participate in the trial, received a study iPad and were asked to play the video game loaded on the iPad for a minimum of 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of the MiCK Assay for Apoptosis in AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~patients with newly diagnosed acute myeloid leukemia (AML~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- II (Type: None): None
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Three-level Injection Paravertebral Block vs General Anesthesia in Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Samples are collected after patients' written informed consent in accordance with the Declaration of Helsinki and institutional research board approval. Sixty women (ASA I - III) undergoing unilateral mastectomy surgery with axillary dissection (radical lymph node removal or sentinel node biopsy) are enrolled. Exclusion criteria are general infection and local infection at the site of planned puncture, anatomic deformities of the thoracic spine, coagulation disorders, allergy against local anesthetics or contrast agents, such as Iopamiro 300, pregnancy or breast-feeding and BMI ≥ 30 kg/m2.~Exclusion Criteria:~* Patients who did not meet the inclusion criteria.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- general anesthesia (Type: ACTIVE_COMPARATOR): fentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
- paravertebral block (Type: EXPERIMENTAL): a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Patient \> 18 years old~* Histologically confirmed diagnosis of melanoma~* Previously treated or previously untreated metastatic melanoma by AJCC staging criteria~* Presence of an index lesion \> 1 cm amenable to hypofractionated radiotherapy and at least one other additional lesion that can be followed for response using RECIST criteria~* ECOG Performance status 0 or 1~* Signed informed consent document~* Ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold position for treatment)~Exclusion Criteria~* Prior systemic therapy within 14 days of study enrollment. Patients must be adequately recovered from prior systemic therapy side effects as deemed by the PI.~* Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)~* Presence or history of central nervous system metastasis (including brain)~* Long-term use of systemic corticosteroids~* Prior RT that precludes the delivery of hypofractionated radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab and Radiotherapy (8 Gy x 2) (Type: EXPERIMENTAL): None
- Ipilimumab and Radiotherapy (8 Gy x 3) (Type: EXPERIMENTAL): None
- Ipilimumab and Radiotherapy (6 Gy x 2) (Type: EXPERIMENTAL): None
- Ipilimumab and Radiotherapy (6 Gy x 3) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic melanoma, meeting any of the following criteria:~  * Progressive disease after chemotherapy, radiotherapy, surgery, or immunotherapy~ * No longer responding to standard therapy OR have refused standard therapy~* Unresectable disease~* Measurable or evaluable disease~* No clinical ascites~* No symptomatic pleural effusion~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 12 weeks~* Karnofsky performance status 70-100%~* Bilirubin ≤ 3.0 mg/dL~* Albumin ≥ 3.0 g/dL~* Alkaline phosphatase \< 5 times upper limit of normal (ULN)~* Serum glucose \> 60 mg/dL~* Amylase \< 1.5 times ULN~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* No New York Heart Association class III-IV heart failure~* No serious infection requiring treatment with antibiotics~* No known allergy to E. coli drug products (e.g., sargramostim \[GM-CSF\])~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 forms of effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 4 weeks since prior anticancer therapy~* At least 4 weeks since prior surgery and recovered~* No concurrent participation in another investigational drug study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- ADI-PEG 20 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete